Neurobiology of Disease

Deranged Calcium Signaling and Neurodegeneration in Spinocerebellar Ataxia Type 3

Xi Chen, Tie-Shan Tang, Huiping Tu, Omar Nelson, Mark Pook, Robert Hammer, Nobuyuki Nukina, and Ilya Bezprozvanny

Departments of Physiology and Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas 75390, School of Health Sciences and Social Care, Brunel University, Uxbridge, Middlesex UB8 3PH, United Kingdom, and Laboratory for Structural Neuropathology, RIKEN Brain Science Institute, Saitama 351-0198, Japan

Spinocerebellar ataxia type 3 (SCA3), also known as Machado–Joseph disease (MJD), is an autosomal-dominant neurodegenerative disorder caused by a polyglutamine expansion in ataxin-3 (ATX3; MJD1) protein. In biochemical experiments, we demonstrate that mutant ATX3exp specifically associated with the type 1 inositol 1,4,5-trisphosphate receptor (InsP3R1), an intracellular calcium (Ca2+) release channel. In electrophysiological and Ca2+ imaging experiments, we show that InsP3R1 was sensitized to activation by InsP3 in the presence of mutant ATX3exp. We found that feeding SCA3-YAC-84Q transgenic mice with dantrolene, a clinically relevant stabilizer of intracellular Ca2+ signaling, improved their motor performance and prevented neuronal cell loss in pontine nuclei and substantia nigra regions. Our results indicate that deranged Ca2+ signaling may play an important role in SCA3 pathology and that Ca2+ signaling stabilizers such as dantrolene may be considered as potential therapeutic drugs for treatment of SCA3 patients.

Key words: calcium signaling; neurodegeneration; ataxin-3; spinocerebellar ataxia type 3; SCA3; Machado–Joseph disease; MJD1; transgenic mouse; stereology; dantrolene

Introduction

Spinocerebellar ataxia type 3 (SCA3), also known as Machado–Joseph disease (MJD), is an autosomal-dominant neurodegenerative disorder that belongs to a group of polyglutamine [poly(Q)]-expansion diseases (Cummings and Zoghbi, 2000; Gusella and MacDonald, 2000; Zoghbi and Orr, 2000). The symptoms of SCA3 include gait ataxia, dysarthria, dysmetria, hyperreflexia, dystonia, and ophthalmoplegia (Coutinho and Andrade, 1978). The brain regions most affected in SCA3/MJD are dentate and pontine nuclei, internal portion of globus pallidus, subthalamic nucleus, substantia nigra (SN), and spinocerebellar tracts (Stevanin et al., 2000). At molecular level, the cause of SCA3 is a poly(Q) expansion in the C-terminal of ataxin-3 (ATX3; MJD1) protein (Kawaguchi et al., 1994; Paulson et al., 1997a). The ataxin-3 is a 43 kDa cytosolic protein that contains N-terminal Josephin domain and two ubiquitin-interactions motifs (Scheel et al., 2003; Nicastro et al., 2005). Poly(Q)-expansion occurs in C-terminal region of ataxin-3 that does not contain any known functional motifs. Despite intense efforts, the cellular pathogenic mechanism of SCA3 remains unclear.

Huntington’s disease (HD) is another member of poly(Q)-expansion disease family, which is caused by a poly(Q) expansion in the context of Huntingtin protein (Htt). In our previous studies, we demonstrated that mutant Httexp protein specifically binds to and activates type 1 inositol 1,4,5-trisphosphate receptor (InsP3R1) (Tang et al., 2003). From these results, we proposed that deranged Ca2+ signaling may play an important role in HD pathogenesis (Bezprozvanny and Hayden, 2004). Here, we set out to investigate whether abnormal Ca2+ signaling also plays a role in SCA3 pathogenesis.

In a series of biochemical and functional experiments, we investigated interactions between ataxin-3 and InsP3R1. We extended these findings to the analysis of SCA3-YAC-84Q mouse model. Obtained results suggested that deranged neuronal Ca2+ signaling plays a significant role in SCA3 pathology; calcium signaling stabilizers may be considered as potential therapeutic drugs for the treatment of SCA3 patients.
Materials and Methods
SCA3 mouse colonies. Generation of SCA3-YAC-15Q and SCA3-YAC-84Q mice have been previously described (Cemal et al., 2002). For our studies, SCA3-YAC-84Q mouse was recreated by in vitro fertilization using C57Bl/6 mouse strain egg and SCA3-YAC-84Q mouse frozen sperm. All the procedures involving mice were approved by Institutional Animal Care and Use Committee of University of Texas Southwestern, in accord with the National Institutes of Health Guidelines for the Care and Use of Experimental Animals.

Human primary fibroblast lines. Primary human fibroblasts (hF-SCA3) derived from a 38-year-old symptomatic SCA3 patient (subject GM06151) and the human fibroblasts (hFs) from healthy individual (subject GM02185C) were obtained from Coriell Cell Repositories (Coriell Institute for Medical Research).

In vitro binding experiments. Enhanced green fluorescent protein (EGFP)-ATX3–19Q, EGFP-ATX3–77Q, and EGFP-ATX3–127Q expression plasmids have been previously described (Wang et al., 2000), Glutathione S-transferase (GST)-IC10 expression plasmid (amino acids F267–A2749 of rat InsP₃R1) has been previously described (Tang et al., 2003). GST and GST-IC10 proteins were expressed in the BL21 Escherichia coli strain and purified on glutathione-agarose beads. EGFP-ATX3–19Q/77Q/127Q proteins were expressed in HEK293 cells by calcium phosphate transfection. Forty-eight hours after transfection, HEK293 cells were collected with ice-cold PBS and solubilized for 30 min at 4°C in extraction buffer A [1% 3-[3-cholamidopropyl]-dimethylammonio]-1-propanesulfonate (CHAPS), 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na₂HPO₄, 1.4 mM KH₂PO₄, pH 7.2, 5 mM EDTA, 5 mM EGTA, and protease inhibitors]. Extracts were clarified by centrifugation for 20 min at 100,000 × g and incubated for 1 h at 4°C with GST or GST-IC10 proteins. Beads were washed three times with extraction buffer A. Attached proteins were analyzed by Western blotting with anti-green fluorescent protein (GFP) monoclonal antibodies.

Full-length rat InsP₃R1 (RT1)-encoding baculoviruses were previously described (Tu et al., 2002). The EGFP-ATX3–19Q, EGFP-ATX3–77Q, and EGFP-ATX3–127Q proteins were transiently expressed in HEK293 cells as described above and solubilized in 1% CHAPS. The mixture of RT1 and ataxin-3 containing lysates was precipitated with anti-InsP₃R1 polyclonal antibody (T443) (Kaznacheyeva et al., 1998) attached to protein A-Sepharose beads and analyzed by Western blotting with anti-GFP monoclonal antibodies. Preimmune sera (P) were used in control immunoprecipitation experiments.

The full-length rat type 1 ryanodine receptor (RyanR1) expression plasmid was a kind gift from Dr. Andrew Marks (Columbia University, New York, NY). The RyanR1 expression plasmids were cotransfected with EGFP-ATX3–19Q and EGFP-ATX3–127Q plasmids into HEK293 cells. The lysates from transfected cells were extracted in 1% CHAPS as described above, precipitated with anti-Atx3 monoclonal antibodies (H9) (Millipore; MAB 5360) and analyzed by the Western blotting with anti-RyanR monoclonal antibodies (Affinity BioReagents; MA3–925).

Planar lipid bilayer experiments. Single-channel recordings of recombinant InsP₃R1 (RT1) were performed as previously described (Tang et al., 2003; Tu et al., 2005a,b) at 0 mV transmembrane potential using 50 mM KCl, 4.3 mM Na₂HPO₄, 1.4 mM KH₂PO₄, pH 7.2, 5 mM EDTA, 5 mM EGTA, and protease inhibitors. In the cis-chamber, 110 mM Tris dissolved in HEPES, pH 7.35, 0.5 mM Na₃ATP, pCa 6.7 (0.2 mM EGTA plus 0.14 mM CaCl₂) (Bezprozvanny et al., 1991). InsP₃R1 were activated by addition of 100 nM InsP₃ (Alexis) to the cis-chamber as indicated in the text. The codon sequences of ATX3–19Q/77Q/127Q proteins were subcloned into pMAL2 bacterial expression vector (New England Biolabs). Maltose-binding protein (MBP), MBP-ATX3–19Q, and MBP-ATX3–77Q–127Q proteins were expressed in BL21 E. coli, purified on amylose resin (New England Biolabs) followed by gel filtration on Sephadex-20 column (AKTA FPLC; GE Healthcare). The proteins were dialyzed overnight against cis-recording buffer (110 mM Tris/HEPES, pH 7.35), and added in 1 µl volume (0.3 mg/ml protein with addition of 0.02 µl ruthenium red) directly to the cis-side of the bilayer containing InsP₃R1 without stirring. Exposure of InsP₃R1 to the test proteins was terminated 2–3 min after addition by stirring the cis-chamber for 30 s (1:3000 dilution of test protein stocks). The InsP₃R1 single-channel currents were amplified (Warner OC-725), filtered at 1 kHz by a low-pass eight-pole Bessel filter, digitized at 5 kHz (Digidata 1200; Molecular Devices), and stored on computer hard drive and recordable optical discs. For off-line computer analysis (pClamp 6; Molecular Devices), currents were filtered digitally at 500 Hz. For presentation of the current traces, data were filtered at 200 Hz.

Coexpression and functional reconstitution of ATX3–RT1 to planar lipid bilayers. Full-length ATX3–19Q and ATX3–77Q constructs were subcloned into pFastBac1 vector (Invitrogen). The ATX3–19Q and ATX3–77Q baculoviruses were generated and amplified using Bac-to-Bac system according to the instructions of the manufacturer (Invitrogen). Expression in Sf9 cells was confirmed by Western blotting with anti-Atx3 monoclonal antibodies H9. The Sf9 cells were coinjected with baculoviruses encoding InsP₃R1 (RT1) and ATX3–19Q or ATX3–77Q proteins. The microsomes prepared from coinjected Sf9 cells were solubilized in extraction buffer A and used in immunoprecipitation experiments with anti-InsP₃R1 polyclonal antibodies (T443) (Kaznacheyeva et al., 1998) attached to protein A-Sepharose beads. The precipitated samples were analyzed by Western blotting with anti-Atx3 monoclonal antibodies H9. The microsomes from the RT1:ATX3–19Q and RT1:ATX3–77Q coinjected Sf9 cells were fused to bilayers and the bilayer current recordings, and analysis was performed as described above.

Cis²⁺ imaging experiments. The rat medium spiny neuronal (MSN) cultures on poly-d-lysine (Sigma–Aldrich)-coated 12 mm round glass coverslips were established as previously described (Tang et al., 2003). The 5 µM ARA-C (cytosine arabinoside) (Sigma–Aldrich) was added at 2–4 h in vitro (DIV) to inhibit glial cell growth. ATX3–19Q, ATX3–77Q, and ATX3–127Q expression plasmids in pCDNA3 vector were generated by subcloning from EGFP-ATX3 plasmids described above. At 20 DIV, the MSN cultures were transfected by the calcium phosphate method with EGFP-C3 plasmid (Clontech) or a 1:3 mixture of EGFP:ATX3 expression plasmids as indicated in the text. Forty-eight hours after transfection, the MSN neurons were loaded with 5 µM fura-2 AM (Invitrogen) in artificial CSF (ACSF) (140 mM NaCl, 5 mM KCl, 1 mM MgCl₂, 2 mM CaCl₂, 10 mM HEPES, pH 7.3) for 45 min at 37°C. For imaging experiments, the coverslips were mounted onto a recording/perfusion chamber (RC-26G; Warner Instruments) maintained at 37°C (PHi; Warner Instruments), positioned on the movable stage of an Olympus IX-70 inverted microscope, and perfused with ACSF media by gravity flow. After GFP imaging, the coverslip was washed extensively with Ca²⁺-free ACSF (omitted CaCl₂ from ACSF and supplemented with 100 µM EGTA). In Ca²⁺ imaging experiments, the MSN cells were intermittently excited by 340 and 380 nm UV light (DeltaRAM illuminator; PTI) using a fura-2 dichroic filter cube (Chroma Technology) and 60× UV-grade oil-immersion objective (Olympus). The emitted light was collected by an epifluorescence (PTI) and an additional set of filters were digitized by ImageMaster Pro software (PTI). Baseline (6 min) measurements were obtained before bath application of 10 µM 3,5-dihydroxyphenylglycine (3,5-DHPG) (Tocris) dissolved in Ca²⁺-free ACSF. The DHPG solutions were prewarmed to 37°C before application to MSNs. Images at 340 and 380 nm excitation wavelengths were captured every 5 s and shown as 340/380 image ratios at time points as indicated. Background fluorescence was determined according to the recommendations of the manufacturer (PTI) and subtracted. Bradykinin (BK)-induced Ca²⁺ release was measured in primary human fibroblasts by following similar procedures as we previously described (Nelson et al., 2007).

Analysis of transgenic ATX3 expression. The expression and subcellular localization of ATX3 was performed as previously described for human samples (Paulson et al., 1997b). Ten-month-old SCA3-YAC-15Q mice and age-matched SCA3-YAC-84Q mice were terminally anesthetized by pentobarbital with the dosage of 60 mg/kg and perfused transcardially with 20 ml of 0.9% saline followed by 100 ml of fixative (4% paraformaldehyde in 0.1 M PBS, pH 7.4). The brains were removed from skull and postfixed with 4% paraformaldehyde in 0.1 M PBS, pH 7.4, overnight at 4°C, and then infiltrated in 20–30% (v/v) sucrase in PBS at 4°C for 24–48 h until falling to the bottom. The brains were frozen on dry ice and cut to 30-µm-thick coronal sections using a Leica SM2000R sliding microtome. The brain sections were treated with 1% hydrogen peroxide (H₂O₂) in PBS for 30 min, blocked with normal goat serum (Vector
Laboratories) diluted 1:100 in PBST (0.3% Triton X-100) for 30 min, and then stained with human-specific anti-ATX3 polyclonal antibodies (Paulson et al., 1997a) (1:5000 dilution; a kind gift from Dr. Henry Paulson, University of Michigan, Ann Arbor, MI) overnight at room temperature. After being washed with PBS three times for 10 min each time, the sections were stained with biotinylated goat anti-rabbit IgG reagent (Vector Laboratories) for 1 h at room temperature. After PBS washing three times for 10 min each time, the signals were amplified with Vectastain Elite ABC reagent (Vector Laboratories) prepared in PBST and then detected with DAB (3,3′-diaminobenzidine) substrate kit (Vector Laboratories). The immunohistochemical pictures were taken in bright field under Nikon 60× oil objective.

In parallel experiments, the sections from 12-month-old SCA3-YAC-84Q mice and 14-month-old SCA3-YAC-15Q were stained with anti-ATX3 monoclonal antibody clone I1H (1:1000 dilution; Millipore; MAB 5360), followed by biotinylated anti-mouse IgG reagent (1:250 dilution; Vector Laboratories) (M.O.M. kit). Signal was amplified with the ABC Elite kit (Vector Laboratories) and detected with diaminobenzidine (Vector Laboratories). The immunohistochemical pictures were taken as described above.

Brain immunoprecipitations.Brains of wild-type (WT) and SCA3-YAC-84Q mice were collected out of skull. After cerebella were taken away, the brain samples were homogenized and solubilized at 4°C for 2 h in extraction buffer A (1% CHAPS, 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, pH 7.2, 5 mM EDTA, 5 mM EGTA, and protease inhibitors). The homogenates were cleared by 30 min centrifugation at 50,000 rpm in TI-100 and incubated with anti-ATX3 monoclonal antibodies I1H (Millipore; MAB 5360) attached to protein A/G PLUS-Agarose (Santa Cruz Biotechnology) at 4°C for 3 h. The resulting beads were washed with extraction buffer A and analyzed by Western blotting with anti-Insp, R1 monoclonal antibody (University of California at Davis/National Institute of Neurological Disorders and Stroke/National Institute of Mental Health NeuroMab Facility; clone D218/14). One twenty-fifth of each immunoprecipitate (IP) lysate was loaded as input.

Drug delivery in mice. Danotrelin was delivered to mice by an approach that we used previously in tetrabenazine trial in YAC128-HD mice (Tang et al., 2007). Briefly, groups of wild-type and SCA3-YAC-84Q mice were fed with 100 µg of danotrelin suspended in 50 µl of PBS with 2% corn flour resulting in the dosage 5 mg/kg. The control groups were fed with 2% corn flour in PBS. All mice were fed orally twice a week from 2% corn flour resulting in the dosage 5 mg/kg. The control groups were fed with 2% corn flour in PBS. All mice were fed orally twice a week from 2 to 12 months of age. To determine the concentration of danotrelin in mouse brains, five wild-type mice of 2 months of age were fed with danotrelin for 2 months with the same dosage (5 mg/kg) and anesthetized 30 min after the last danotrelin feeding. The blood samples of five mice were solubilized in a tube containing 50 µl of ACD solution (2.2 g of sodium citrate; 0.8 g of citric acid, monohydrate; 2.24 g of glucose, anhydrous dissolved in DH2O, to the final volume 100 ml). After spinning the blood samples at 4°C, 10,000 rpm for 10 min, plasma was isolated and transferred to −80°C immediately. The brains were collected at the same time and snap frozen in liquid nitrogen. The plasma and brain samples from each mouse were numbered and shipped on dry ice to the core facility of the Department of Biochemistry of University of Texas Southwestern for analysis by HPLC.

Motor coordination assessments in mice. The motor coordination experiments were performed as previously described for the tetrabenazine trial in YAC128-HD mice (Tang et al., 2007). The “beam walking” assay was performed using a home-made experimental setup. The setup was a 17 mm round plastic beam, 11 mm round plastic beam, and 5 mm square wood beam were used in our studies. At each time point, the mice were trained on beams for 3 consecutive days (four trials per day) to traverse the beam to the enclosed box. Once the stable baseline of performance was obtained, the mice were tested in three consecutive trials on 17 and 11 mm round plastic beams and 5 mm square wood beam, in each case progressing from the widest to the narrowest beam. The latency to traverse the middle 80 cm of each beam and the number of times the hindfeet slipped off each beam were recorded for each trial. For each measurement, the mean scores of the three trials for each beam were used in the analysis. For the footprint test, the forepaws and hindpaws of the mice were coated with purple and green nontoxic paints, respectively. The mice were trained to walk along a 50-cm-long, 10-cm-wide, paper-covered runway (with 10-cm-high walls) into an enclosed box. All the mice were given three runs per day for 3 consecutive days. A fresh sheet of white paper was placed on the floor of the runway for each run. The footprint patterns were assessed quantitatively by the measurements of stride length and frontpaw/hindpaw overlap as we described previously (Tang et al., 2007).

Neuropathological assessments in mice. The neuropathological assessments were performed as previously described (Tang et al., 2007). After all the behavioral testings (13.5 month time point), the mice were terminally anesthetized by pentobarbital and perfused transcardially as described above. All brains were removed from skull, weighed, and transferred to postfixative (4% paraformaldehyde in 0.1 ss PBS, pH 7.4). The brains were processed and cut into 30-µm-thick coronal sections as described above. The coronal slices spaced 90 µm apart throughout the entire brain were stained with anti-tyrosine hydroxylase (TH) monoclonal antibody (1:400 dilution; Millipore). Biotinylated anti-mouse IgG reagent was used in all the staining as the secondary antibodies (1:250 dilution; Vector Laboratories) (M.O.M. kit). Signal was amplified with an ABC Elite kit (Vector Laboratories) and detected with diaminobenzidine (Vector Laboratories). The immunohistochemical pictures were taken as described above.

Results

Mutant ataxin-3 specifically binds to InsP, R1 in vitro

To determine whether ATX3 expression behavior as compared to Htt and also binds to the InsP, R1 C-terminal region, we expressed EGFP-ATX3–19Q, EGFP-ATX3–77Q, and EGFP-ATX3–127Q proteins (Wang et al., 2008) in HEK293 cells and performed a series of GST pulldown experiments with bacterially expressed InsP, R1 C-terminal fragment GST-IC10 (amino acids F6267 to A7249 of rat InsP, R1). The precipitated samples were analyzed by Western blotting with anti-GFP monoclonal antibodies. We found that GST-IC10, but not GST, specifically associated with GFP-ATX3–19Q, EGFP-ATX3–77Q and GFP-ATX3–127Q proteins (Fig. 1A). Similar to Htt (Tang et al., 2003), association of ataxin-3 with IC10 fragment was dependent on poly(Q) expansion because wild-type EGFP-ATX3–19Q protein did not bind to GST-IC10 (Fig. 1A). In the next series of experiments, we tested the association of full-length InsP, R1 with ataxin-3. In these experiments, we expressed full-length rat InsP, R1 (RT1) in S9 cells by baculoviral infection and solubilized recombinant InsP, R1 (RT1) in 1% CHAPS. The EGFP-ATX3–19Q, EGFP-ATX3–77Q, and EGFP-ATX3–127Q proteins were transiently expressed in HEK293 cells as described above and solubilized in 1% CHAPS. The mixture of RT1 and ataxin-3 containing lysates was precipitated with anti-InsP, R1 rabbit polyclonal antibodies (T443) (Kaznacheeva et al., 1998) and analyzed by Western blotting with anti-GFP monoclonal antibodies. Preimmun sera (P/S) were used in control immunoprecipitation experiments. We found that full-length InsP, R1 associated with EGFP-ATX3–77Q and EGFP-ATX3–127Q mutant proteins, but not with the wild-type EGFP-ATX3–19Q protein (Fig. 1B). Thus, association of full-length InsP, R1 with ataxin-3 also depends on poly(Q)-expansion in ataxin-3 sequence.
In addition to InsP₃R channels, Ca²⁺ release from neuronal endoplasmic reticulum can also be mediated by RyanR channels. The InsP₃R and RyanR have significant sequence homology in the C-terminal region, and it is possible that ATX3exp also binds RyanR. To test this possibility, we cotransfected full-length rat RyanR1 expression plasmids together with EGFP-ATX3–19Q or EGFP-ATX3–127Q plasmids to HEK293 cells. The lysates from transfected cells were solubilized in 1% CHAPS and immunoprecipitated with anti-Atx3 monoclonal antibodies. Western blotting with anti-RyanR pseudocolor images (Fig. 3A). The transfected cells were identified by GFP imaging (Fig. 3A, first column) before collecting imaging data. A small response to DHPG application at this concentration was observed in MSNs transfected with ATX3–19Q (Fig. 3A, second row; D, E). In contrast, significant response to 10 μM DHPG was observed in MSNs transfected with ATX3–77Q plasmid (Fig. 3A, second row; D, E). Even stronger response to DHPG was observed in MSNs transfected with ATX3–127Q plasmid (Fig. 3A, fourth row; H, I). On average, after the addition of 10 μM DHPG, the peak 340/380 ratios were significantly (p < 0.01) higher than basal 340/380 ratios in ATX3–77Q (Fig. 2, K). Thus, we concluded that overexpression of ATX3exp mutant protein, but not of ATX3 wild-type protein, sensitizes InsP₃-sensitive Ca²⁺ stores in cultured neurons.

To further investigate functional effects of ATX3exp on Ca²⁺ signaling in cells and to establish the relevance of our results for human disease, we performed a series of fura-2 Ca²⁺ imaging experiments with primary human fibroblasts from a healthy individual (hF) and a symptomatic SCA3 patient with 74Q expansion in ataxin-3 gene (hF-SCA3) (Fig. 4A). We discovered that application of 300 nM BK, an agonist of InsP₃-sensitive receptor,
induced much larger Ca\(^{2+}\) responses in hF-SCA3 cells than in control hF cells (Fig. 4B, C). On average, the amplitude of BK-induced Ca\(^{2+}\) responses was equal to 318 ± 71 nM Ca\(^{2+}\) (\(n = 43\)) in control hF cells and 573 ± 108 nM Ca\(^{2+}\) (\(n = 37\)) in hF-SCA3 cells, which was significantly higher (\(p < 0.05\)). From these experiments, we concluded that expression of mutant human ataxin-3 proteins has potentiating effect on InsP3R-mediated Ca\(^{2+}\) release in SCA3 patient fibroblasts, consistent with our analysis of Ca\(^{2+}\) signals in cultured rat MSN transfected with mutant ATXexp (Fig. 3).

**Table 1. Dantrolene trial in SCA3-YAC-84Q mice**

<table>
<thead>
<tr>
<th>Group no.</th>
<th>Group name</th>
<th>No. of female mice</th>
<th>Mouse genotype</th>
<th>Single dose (2/week) (50 (\mu l))</th>
<th>Drug dosage (mg (\cdot) kg(^{-1}) (\cdot) 3 d(^{-1}))</th>
<th>Brain weight (g)</th>
<th>Pn counts</th>
<th>SN-TH counts</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>WT-Ctrl</td>
<td>10</td>
<td>WT</td>
<td>50 (\mu l) of PBS</td>
<td>PBS</td>
<td>0.500 ± 0.008</td>
<td>43,368 ± 1811</td>
<td>11,026 ± 284</td>
</tr>
<tr>
<td>2</td>
<td>WT-Dan</td>
<td>7</td>
<td>WT</td>
<td>100 (\mu g) of dantrolene</td>
<td>5 mg of dantrolene</td>
<td>0.501 ± 0.004</td>
<td>43,659 ± 2203</td>
<td>11,202 ± 254</td>
</tr>
<tr>
<td>3</td>
<td>SCA3-Ctrl</td>
<td>8</td>
<td>SCA3-YAC-84Q</td>
<td>50 (\mu l) of PBS</td>
<td>PBS</td>
<td>0.451 ± 0.007</td>
<td>37,021 ± 1000</td>
<td>9384 ± 250</td>
</tr>
<tr>
<td>4</td>
<td>SCA3-Dan</td>
<td>10</td>
<td>SCA3-YAC-84Q</td>
<td>100 (\mu g) of dantrolene</td>
<td>5 mg of dantrolene</td>
<td>0.470 ± 0.007</td>
<td>43,642 ± 1725</td>
<td>10,699 ± 239</td>
</tr>
</tbody>
</table>

Four groups of mice were tested in our experiments. At 2 months of age, WT and SCA3-YAC-84Q mice were divided into two groups each, and drug treatment was initiated. The group number, group name, number and genotype of mice in each group, and dose of single drug treatment (twice/week) are shown for each group. Also shown is the estimated drug dosage in milligrams per kilogram of body weight. The results of neuromonitoring analysis are shown for each group. The average brain weight, Pn neuronal counts, and SN-TH neuronal counts are as mean ± SEM.

**Figure 2.** Mutant ataxin-3 sensitizes InsP\(_3\)R1 to the activation by InsP\(_3\) in bilayers. A, MBP, MBP-ATX3–19Q, and MBP-ATX3–77Q were expressed in bacteria, purified and analyzed by SDS-PAGE electrophoresis and Coomassie staining. The blot of MBP-ATX3–19Q was from a different blot. B, D, Effects of MBP, MBP-ATX3–19Q, and MBP-ATX3–77Q on the activity of recombinant InsP\(_3\)R1 in planar lipid bilayers at 100 nM InsP\(_3\). Each current trace corresponds to 10 s (2 s for expanded traces) of current recording for the same experiment. C, E, The average open probability (\(P_o\)) of InsP\(_3\)R1 at 100 nM InsP\(_3\) in the presence of MBP, MBP-ATX3–19Q, and MBP-ATX3–77Q. The average \(P_o\) was calculated for a 5 s window of time and plotted for the duration of an experiment. The times of InsP\(_3\), MBP, MBP-ATX3–19Q, and MBP-ATX3–77Q additions are shown above the \(P_o\) plot. Data from the same experiment are shown on B and C, and D and E. Similar results were obtained in at least three independent experiments with MBP-ATX3–19Q and MBP-ATX3–77Q.

**Chen et al. Calcium Signaling in SCA3 J. Neurosci., November 26, 2008 • 28(48):12713–12724 • 12717**

**Mutant ataxin-3 associates with InsP\(_3\)R1 in vivo**

To establish a relevance of our findings for SCA3 pathogenesis in vivo, we focused on analysis of SCA3-YAC-84Q mouse model (Cemal et al., 2002). The SCA3-YAC-84Q mice used in these studies have been recreated by in vitro fertilization from a frozen
lysates from SCA3-YAC-84Q mouse brains (data not shown). Very similar staining pattern was observed in both cases. We observed that the pattern of ATX3–84Q transgene expression and nuclear accumulation in the aging SCA3-YAC-84Q mouse brains corresponded closely with the regions most severely affected in SCA3 patients, with abundant nuclear accumulation of ataxin-3 in Pn, SN, and dentate nuclei (Lat) regions (Fig. 5; supplemental Fig. 2, available at www.jneurosci.org as supplemental material). In contrast, nuclear accumulation of ataxin-3 was not detected in striatum (CPu), cortex, and hippocampus (Fig. 5; supplemental Fig. 2, available at www.jneurosci.org as supplemental material) (data not shown), which are the brain regions relatively spared in MJD/SCA3 patients (Stevanin et al., 2000). In SCA3-YAC-15Q mouse brains, ataxin-3 protein was predominantly cytosolic and did not accumulate in the nucleus (Fig. 5; supplemental Fig. 2, available at www.jneurosci.org as supplemental material). Similarly, ataxin-3 was predominantly cytosolic in neurons from 3-month-old SCA3-YAC-84Q mouse brains (data not shown). Therefore, we reasoned that the accumulation of ataxin-3 in aging SCA3-YAC-84Q mouse brains is a late event in the process of SCA3 pathogenesis, which may serve as an indication of the “stressed neurons.” Nuclear accumulation of ataxin-3 does not appear to be required for abnormal Ca\textsuperscript{2+} signaling and most likely reflects pathological processes occurring at end stage of neuronal pathogenesis.

To determine whether ATX3\textsuperscript{exp} forms complex with InsP\textsubscript{3}R1 in vivo, we performed a series of experiments with cortical lysates from wild-type and SCA3-YAC-84Q mouse brains. The expression of ataxin-3 in these cortical lysates was analyzed by anti-Atx3 monoclonal antibodies. Only wild-type mouse Atx3 was detected in cortical lysates from wild-type mouse brains (Fig. 6A). In contrast, both endogenous wild-type Atx3 and transgenic mutant ATX3–84Q were detected in cortical lysates from SCA3-YAC-84Q mouse brains (Fig. 6B–D). In human-specific wild-type Atx3 and transgenic mutant ATX3–84Q were detected in cortical lysates from wild-type mouse brains (Fig. 6E–G). Only wild-type mouse Atx3 was detected in human-specific wild-type Atx3 and transgenic mutant ATX3–84Q were detected in cortical lysates from wild-type mouse brains (Fig. 6H–J). The expression of ataxin-3 in these cortical lysates was analyzed by anti-Atx3 monoclonal antibodies (Fig. 5) or human-specific anti-ATX3 affinity-purified rabbit polyclonal antibodies (Paulson et al., 1997a) (supplemental Fig. 2, available at www.jneurosci.org as supplemental material). Very similar staining pattern was observed in both cases. We observed that the pattern of ATX3–84Q transgene expression and nuclear accumulation in the aging SCA3-YAC-84Q mouse brains corresponded closely with the regions most severely affected in SCA3 patients, with abundant nuclear accumulation of ataxin-3 in Pn, SN, and dentate nuclei (Lat) regions (Fig. 5; supplemental Fig. 2, available at www.jneurosci.org as supplemental material). In contrast, nuclear accumulation of ataxin-3 was not detected in striatum (CPu), cortex, and hippocampus (Fig. 5; supplemental Fig. 2, available at www.jneurosci.org as supplemental material) (data not shown), which are the brain regions relatively spared in MJD/SCA3 patients (Stevanin et al., 2000). In SCA3-YAC-15Q mouse brains, ataxin-3 protein was predominantly cytosolic and did not accumulate in the nucleus (Fig. 5; supplemental Fig. 2, available at www.jneurosci.org as supplemental material). Similarly, ataxin-3 was predominantly cytosolic in neurons from 3-month-old SCA3-YAC-84Q mouse brains (data not shown). Therefore, we reasoned that the accumulation of ataxin-3 in aging SCA3-YAC-84Q mouse brains is a late event in the process of SCA3 pathogenesis, which may serve as an indication of the “stressed neurons.” Nuclear accumulation of ataxin-3 does not appear to be required for abnormal Ca\textsuperscript{2+} signaling and most likely reflects pathological processes occurring at end stage of neuronal pathogenesis.

To determine whether ATX3\textsuperscript{exp} forms complex with InsP\textsubscript{3}R1 in vivo, we performed a series of experiments with cortical lysates from wild-type and SCA3-YAC-84Q mouse brains. The expression of ataxin-3 in these cortical lysates was analyzed by anti-Atx3 monoclonal antibodies. Only wild-type mouse Atx3 was detected in cortical lysates from wild-type mouse brains (Fig. 6A). In contrast, both endogenous wild-type Atx3 and transgenic mutant ATX3–84Q were detected in cortical lysates from SCA3-YAC-84Q mouse brains (Fig. 6B–D). In human-specific wild-type Atx3 and transgenic mutant ATX3–84Q were detected in cortical lysates from wild-type mouse brains (Fig. 6E–G). Only wild-type mouse Atx3 was detected in human-specific wild-type Atx3 and transgenic mutant ATX3–84Q were detected in cortical lysates from wild-type mouse brains (Fig. 6H–J). The expression of ataxin-3 in these cortical lysates was analyzed by anti-Atx3 monoclonal antibodies (Fig. 5) or human-specific anti-ATX3 affinity-purified rabbit polyclonal antibodies (Paulson et al., 1997a) (supplemental Fig. 2, available at www.jneurosci.org as supplemental material). Very similar staining pattern was observed in both cases. We observed that the pattern of ATX3–84Q transgene expression and nuclear accumulation in the aging SCA3-YAC-84Q mouse brains corresponded closely with the regions most severely affected in SCA3 patients, with abundant nuclear accumulation of ataxin-3 in Pn, SN, and dentate nuclei (Lat) regions (Fig. 5; supplemental Fig. 2, available at www.jneurosci.org as supplemental material). In contrast, nuclear accumulation of ataxin-3 was not detected in striatum (CPu), cortex, and hippocampus (Fig. 5; supplemental Fig. 2, available at www.jneurosci.org as supplemental material) (data not shown), which are the brain regions relatively spared in MJD/SCA3 patients (Stevanin et al., 2000). In SCA3-YAC-15Q mouse brains, ataxin-3 protein was predominantly cytosolic and did not accumulate in the nucleus (Fig. 5; supplemental Fig. 2, available at www.jneurosci.org as supplemental material). Similarly, ataxin-3 was predominantly cytosolic in neurons from 3-month-old SCA3-YAC-84Q mouse brains (data not shown). Therefore, we reasoned that the accumulation of ataxin-3 in aging SCA3-YAC-84Q mouse brains is a late event in the process of SCA3 pathogenesis, which may serve as an indication of the “stressed neurons.” Nuclear accumulation of ataxin-3 does not appear to be required for abnormal Ca\textsuperscript{2+} signaling and most likely reflects pathological processes occurring at end stage of neuronal pathogenesis.

To determine whether ATX3\textsuperscript{exp} forms complex with InsP\textsubscript{3}R1 in vivo, we performed a series of experiments with cortical lysates from wild-type and SCA3-YAC-84Q mouse brains. The expression of ataxin-3 in these cortical lysates was analyzed by anti-Atx3 monoclonal antibodies. Only wild-type mouse Atx3 was detected in cortical lysates from wild-type mouse brains (Fig. 6A). In contrast, both endogenous wild-type Atx3 and transgenic mutant ATX3–84Q were detected in cortical lysates from SCA3-YAC-84Q mouse brains (Fig. 6B–D). In human-specific wild-type Atx3 and transgenic mutant ATX3–84Q were detected in cortical lysates from wild-type mouse brains (Fig. 6E–G). Only wild-type mouse Atx3 was detected in human-specific wild-type Atx3 and transgenic mutant ATX3–84Q were detected in cortical lysates from wild-type mouse brains (Fig. 6H–J). The expression of ataxin-3 in these cortical lysates was analyzed by anti-Atx3 monoclonal antibodies (Fig. 5) or human-specific anti-ATX3 affinity-purified rabbit polyclonal antibodies (Paulson et al., 1997a) (supplemental Fig. 2, available at www.jneurosci.org as supplemental material). Very similar staining pattern was observed in both cases. We observed that the pattern of ATX3–84Q transgene expression and nuclear accumulation in the aging SCA3-YAC-84Q mouse brains corresponded closely with the regions most severely affected in SCA3 patients, with abundant nuclear accumulation of ataxin-3 in Pn, SN, and dentate nuclei (Lat) regions (Fig. 5; supplemental Fig. 2, available at www.jneurosci.org as supplemental material). In contrast, nuclear accumulation of ataxin-3 was not detected in striatum (CPu), cortex, and hippocampus (Fig. 5; supplemental Fig. 2, available at www.jneurosci.org as supplemental material) (data not shown), which are the brain regions relatively spared in MJD/SCA3 patients (Stevanin et al., 2000). In SCA3-YAC-15Q mouse brains, ataxin-3 protein was predominantly cytosolic and did not accumulate in the nucleus (Fig. 5; supplemental Fig. 2, available at www.jneurosci.org as supplemental material). Similarly, ataxin-3 was predominantly cytosolic in neurons from 3-month-old SCA3-YAC-84Q mouse brains (data not shown). Therefore, we reasoned that the accumulation of ataxin-3 in aging SCA3-YAC-84Q mouse brains is a late event in the process of SCA3 pathogenesis, which may serve as an indication of the “stressed neurons.” Nuclear accumulation of ataxin-3 does not appear to be required for abnormal Ca\textsuperscript{2+} signaling and most likely reflects pathological processes occurring at end stage of neuronal pathogenesis.
Dantrolene alleviates motor coordination deficits in SCA3-YAC-84Q mice

Biochemical and functional interactions between ATX3<sup>exp</sup> and SCA3-YAC-84Q mice

Dantrolene is a skeletal muscle relaxant widely used in the clinic to treat malignant hyperthermia (MH) and muscle spasticity (Krause et al., 2004). When used to treat MH, dantrolene acts by inhibiting excessive Ca<sup>2+</sup> release from sarcoplasmic reticulum in skeletal muscles. In neuronal cells, dantrolene has similar inhibitory effects on Ca<sup>2+</sup> release from the endoplasmic reticulum (Makarewicz et al., 2003). One molecular target of dantrolene in muscle and neuronal cells is RyanR, an intracellular Ca<sup>2+</sup> release channel. It has been also shown that azumolene, a structurally similar analog of dantrolene, inhibits store-operated Ca<sup>2+</sup> entry (Zhao et al., 2006). Thus, dantrolene can be considered a general Ca<sup>2+</sup> signaling stabilizer. In experiments with cultured neuronal cells and in animal models, dantrolene has been shown to have neuroprotective effect in a variety of excitotoxic paradigms (Frandsen and Schousboe, 1991; Berg et al., 1995; Mody and MacDonald, 1995; Wei and Perry, 1996; Guo et al., 1999; Niebauer and Gruenthal, 1999; Schneider et al., 2001; Popescu et al., 2002; Makarewicz et al., 2003). These results lead us to evaluate potential beneficial effects of dantrolene in SCA3-YAC-84Q mouse model.

In our studies, 100 μg of dantrolene was suspended in PBS and orally delivered to WT and SCA3-YAC-84Q (SCA3) mice twice a week starting at 2 months time point until all the mice were 12 months of age (Table I, groups 2 and 4). The drug feeding was stopped after 12 month time point and was followed by a 1.5 month washout period. Control groups of WT and SCA3 mice were fed with PBS alone at the same time (Table I, groups 1 and 3). The effectiveness of drug delivery was determined by 2 months of “drug dosage” trial. We found that, 30 min after feeding, dantrolene concentration in blood plasma was 1081.25 ± 261.91 ng/ml and in brain it was 23.2 ± 4.2 ng/g (67 nm). Thus, we concluded that dantrolene accessed to the systemic circulation effectively from the gastrointestinal system, but penetrated blood–brain barrier poorly, which is in agreement with the previous findings in the animal model of cerebral ischemia in gerbils (Wei and Perry, 1996).

The behavioral assessment of all four groups of mice was performed by using “beam walk” assay (for details, see Materials and Methods for details). Basal beam-walking performance was determined before initiation of drug feeding when the mice were 2 months of age. The beam-walking data were collected at 2, 4, 7.5, 10, 12, and 13.5 (washout) months of age. As in our previous studies (Tang et al., 2007), three kinds of beams (17 mm round, 11 mm round, and 5 mm square) were used for testing. The “latency” and “number of foot slips” were determined on each beam. When results were analyzed, we found that control group of SCA3 mice (fed with PBS) exhibited a progressive impairment in beam-walking ability (longer beam traverse latencies and increased number of foot slips) with age and beam difficulty compared with control group of WT mice. The significant differences (p < 0.05) between beam performance of control SCA3 and control WT groups were observed at 10, 12, and 13.5 months of age on 17 mm round beam (Fig. 7A, B); at 7.5, 10, 12, and 13.5 months of age on 11 mm round beam and 5 mm square beam (Fig. 7C–F). Feeding dantrolene to WT mice had no significant effect on balance beam performance of these mice (Fig. 7A–F). However, feeding dantrolene to SCA3 mice improved their beam-walking performance, significantly (p < 0.05) shortening the latencies and decreasing the foot slip numbers (Fig. 7A–F). Significant differences (p < 0.05) of latency between SCA3 control group and dantrolene-fed SCA3 group were detected at 12 and 13.5 months of age on 17 round beam (Fig. 7A); at 10, 12, and 13.5 months of age on 11 mm round beam and 5 mm square beam.
beam (Fig. 7C,E). At 7.5, 10, and 12 month points, the number of foot slips of dantrolene-fed SCA3 mice on all three beams were almost identical with control WT mice (Fig. 7B,D,F). We noticed that, after dantrolene withdrawal, the performance of both WT and SCA3 groups of mice was impaired, with increased latencies and elevated numbers of foot slips (Fig. 7A–F). This phenomenon is most likely to be attributable to the removal of the sedative effect of dantrolene, which resulted in anxiousness of the mice. Despite this “withdrawal effect,” dantrolene-fed SCA3 mice still performed better than control SCA3 mice in most tasks at the 13.5 month time point (Fig. 7A–F).

While conducting beam-walking assays, we observed that some aging mice exhibited periods of “crawling behavior” (defined as prolonged contact between the thorax and abdomen of the mice and beam surface, with the mice using forelimbs to drag themselves along the beam). Two mice in SCA3 control group crawled on 11 mm round and 5 mm square beams at 10 months time point, three mice in SCA3 control group crawled on 11 mm round beam and 5 mm square beam at 12 and 13.5 months of age, and two mice in SCA3 dantrolene-fed group crawled on 5 mm square beam at 12 and 13.5 months of age. Furthermore, one mouse in SCA3 control group fell off 5 mm square beam when tested at 12 and 13.5 month time points (Fig. 7E,F). In contrast, none of the mice in WT groups exhibited crawling behavior or fell off the beams at any age tested. The incidence of crawling behavior was consistent with a general performance of these mice in balance beam assay, with SCA3 control group performing the worst, dantrolene-fed SCA3 group performing better, and all the wild-type mice traversing the beams without crawling.

At the conclusion of beam-walking behavioral experiments (13.5 months of age), we assessed gait abnormalities in the four groups of mice by footprint pattern analysis (Fig. 8A). The footprint patterns were assessed quantitatively by the measurements of stride length and front/hind footprint overlap as we previously described (Tang et al., 2007). We found that the stride length of SCA3 control mice was very significantly ($p < 0.001$) shorter than WT control littermates (Fig. 8B). Dantrolene feeding significantly ($p < 0.01$) increased the stride length of SCA3 mice, but had no obvious effects on stride length of WT mice (Fig. 8B). We further found that front/hind footprint overlap was significantly higher in SCA3 control group than

**Figure 5.** Expression and localization of ataxin-3 in aging SCA3-YAC-15Q and SCA3-YAC-84Q mouse brains. Expression and distribution of ataxin-3 protein were assessed in brains from 12-month-old SCA3-YAC-84Q mice and 14-month-old SCA3-YAC-15Q mice. The coronal sections from these brains were stained with ataxin-3 monoclonal antibody and analyzed by light microscopy. ATX3 transgenes were found expressed ubiquitously in the mouse brains. In SCA3-YAC-84Q mice, we detected abundant nuclear accumulation of ataxin-3 in Pn (B), SN (D), and dentate nuclei (Lat) (F). In SCA3-YAC-84Q brains, nuclear accumulation of ataxin-3 was also abundantly detected in ventral tegmental area, globus pallidus, superior olivary complex, thalamus, and hypothalamus nuclei (data not shown). In contrast, ataxin-3 did not accumulate in striatum (CPu) (M), cortex and hippocampus of aging SCA3-YAC-84Q brain (data not shown), which are brain regions relatively spared in MJD/SCA3 patients. In SCA3-YAC-15Q mouse, ataxin-3 protein was expressed in a similar pattern but remained predominantly cytosolic and did not accumulate in the nucleus (A, C, E, G). The magnified images of representative cells (framed by black squares) are shown as insets on each panel. Scale bars: outside squares, 50 μm; magnified images (inside squares), 5 μm. Similar results were obtained with two aging brains from SCA3-YAC-15Q and SCA3-YAC-84Q mice.

**Figure 6.** Association of ataxin-3 with InsP$_3$R1 in vivo. A, The expression of endogenous and transgenic ataxin-3 protein in the cortical lysates from WT and SCA3-YAC-84Q mice. Wild-type mouse brains only have endogenous wild-type Atx3, whereas SCA3-YAC-84Q mouse brains have both endogenous wild-type Atx3 and transgenic mutant ATX3–84Q. B, The cortical lysates from WT and SCA3-YAC-84Q mice were precipitated by anti-ataxin-3 mAb and analyzed by Western blotting with anti-InsP$_3$R1 mAb. InsP$_3$R1 was detected in samples precipitated from SCA3-YAC-84Q cortical lysates, but not from wild-type cortical lysates. Empty protein A/G PLUS-Agarose beads were used as negative control in the immunoprecipitation experiments. The input lanes contain 1/25 of the lysates used for IP experiments.
in WT control group (Fig. 8B). In contrast to stride length measurement, footprint overlap deficit was not rescued by feeding dantrolene to SCA3 mice (Fig. 8B).

**Dantrolene protects against neuronal loss in SCA3-YAC-84Q mice**

To further evaluate potential neuroprotective effects of dantrolene, at the conclusion of behavioral analysis (13.5 month time point), the brains from all four groups of experimental mice were removed from skull and weighed after transcardial perfusion. We found that the brains of control SCA3 mice (fed with PBS) weighted significantly less ($p < 0.01$) than the brains of control WT mice group (Fig. 9A, Table 1). Feeding dantrolene to WT mice had no significant effect on brain weight of these mice (Fig. 9A, Table 1), whereas the brain weight of SCA3 mice fed with dantrolene was higher than the brain weight of control SCA3 mice (Fig. 9A, Table 1), although the difference did not reach a level of statistical significance.

To obtain quantitative information about neuronal loss in the experimental mice, we performed stereological analysis of these brains. Our analysis was focused on Pn and SN regions, both of which severely affected in SCA3 patients (Stevanin et al., 2000). Our own experiments confirmed abundant accumulation of ATX3–84Q transgene in neurons from Pn and SN regions in brains from aging SCA3-YAC-84Q mice (Fig. 5; supplemental Fig. 2, available at www.jneurosci.org as supplemental material). For stereological analysis, NeuN-positive neurons in Pn and TH-positive neurons in SN were counted blindly with respect to the nature of slices (genotype and drug treatment). We focused on TH-positive neurons in SN as dopaminergic neurons are most severely affected in SCA3 patients (Stevanin et al., 2000), and our own analysis demonstrated that Atx3–84Q transgene is primarily expressed in SN dopaminergic neurons of SCA3-YAC-84Q mice (data not shown). By stereological analysis, we determined that control SCA3 mice (fed with PBS) showed significant neuronal loss in Pn ($p < 0.05$) and SN ($p < 0.01$) when compared with control WT mice (Fig. 9B, C; Table 1). We further found that feeding of dantrolene had no significant effect on Pn and SN neuronal counts in WT mice; however, dantrolene feeding significantly increased Pn and SN neuronal counts ($p < 0.01$) in SCA3 mice (Fig. 9B, C; Table 1). Our results indicated that feeding with dantrolene protected most Pn and SN neurons from cell death in brains of aging SCA3 mice.

**Discussion**

The causes of neurodegeneration in SCA3 and other poly(Q)-expansion disorders are poorly understood. Similar to other poly(Q)-expansion disorders, mutant ataxin-3 forms nuclear aggregates (Fig. 5), and formation of these aggregates has been proposed to be toxic to the affected neurons (Paulson et al., 1997b; Perez et al., 1999). The nuclear toxicity of ataxin-3 has been supported by recent genetic experiments with transgenic mouse model of SCA3 (Bichelmeier et al., 2007). Consistent with the presence of Josephin domain and ubiquitin-interactions motifs, ataxin-3 binds to polyubiquitylated proteins and displays deubiquitylating activity in vitro (Burnett et al., 2003; Burnett and Pittman, 2005). In agreement
with defects in ubiquitin–proteasomal pathway, impaired proteasomal function has been implicated in SCA3 pathogenesis (Chai et al., 1999). Results of our studies indicate that, in addition to forming “toxic aggregates” and causing “proteasomal deficiency,” mutant ataxin-3 is also able to destabilize neuronal Ca\(^{2+}\) signaling. We found that mutant ataxin-3 directly binds to the InsP\(_3\)R1 (Figs. 1A, B, 6B; supplemental Fig. 1, available at www.jneurosci.org as supplemental material), which may make InsP\(_3\)R1 “gate” easier to open, and thus increases the sensitivity of InsP\(_3\)R1 to activation by InsP\(_3\) in vitro and in cells (Figs. 2–4). The mechanism of ATX3\(_{\text{exp}}\) effects on InsP\(_3\)R1 and Ca\(^{2+}\) signaling in this study is similar to the actions of Htt\(_{\text{exp}}\) we described previously (Tang et al., 2003), and supports the assumption that many poly(Q)-expansion disorders share common pathogenic mechanisms (Cummings and Zoghbi, 2000; Gusella and MacDonald, 2000; Zoghbi and Orr, 2000).

Based on the biochemical and functional interactions between mutant ataxin-3 and InsP\(_3\)R1 (Figs. 1–4, 6), we reasoned that deranged neuronal Ca\(^{2+}\) signaling may contribute to SCA3 pathogenesis. To test this hypothesis, we set out to evaluate the potential benefits of a Ca\(^{2+}\) signaling inhibitor in SCA3-YAC84Q animal model (Cemal et al., 2002). The only specific membrane-permeable inhibitor of InsP\(_3\)R1 is xestospongin C (Gafni et al., 1997). However, xestospongin C is not stable in vivo and not appropriate for animal trials. Thus, instead of targeting InsP\(_3\)R for our animal studies, we decided to target another intracellular Ca\(^{2+}\) release channel, the RyanR. RyanRs are widely expressed in the nervous system (Giannini et al., 1995). The Ca\(^{2+}\) release from intracellular stores in neurons often consists of InsP\(_3\)-induced calcium release (IICR) mediated by InsP\(_3\)R and calcium-induced calcium release (CICR) triggered by the openings of RyanR (Berridge, 1998; Verkhratsky, 2005). Furthermore, RyanR-mediated CICR also serves to amplify Ca\(^{2+}\) signals resulting from influx via NMDAR and voltage-gated Ca\(^{2+}\) channels (Berridge, 1998; Verkhratsky, 2005). Therefore, we reasoned that pharmacological inhibition of RyanR may compensate for enhanced activity of InsP\(_3\)R1 and result in neuroprotective effects in SCA3 mouse model.

To block neuronal RyanR, we selected dantrolene, a clinically relevant inhibitor of RyanR (Krause et al., 2004). It has been also shown that azumolene, a structurally similar analog of dantrolene, inhibits store-operated Ca\(^{2+}\) entry (Zhao et al., 2006). Thus, dantrolene can be considered a general Ca\(^{2+}\) signaling stabilizer. In previous experiments with cultured neuronal cells and in animal models, dantrolene has been shown to have neuroprotective effect in a variety of excitotoxic paradigms (Frandsen and Schousboe, 1991; Berg et al., 1995; Mody and MacDonald, 1995; Wei and Perry, 1996; Guo et al., 1999; Niebauer and Gruenthal, 1999; Schneider et al., 2001; Popescu et al., 2002; Makarewicz et al., 2003). Thus, we set out to investigate potential neuroprotective effects of dantrolene in the mouse model of SCA3. For our trial, we choose to fed the mice with 5 mg/kg dantrolene, which is the typical dosage of oral administration of dantrolene used in humans (4–8 mg·kg\(^{-1}\)·d\(^{-1}\)) (Ward et al., 1986). Pharmacokinetic studies of dantrolene demonstrated that, in healthy conscious volunteers, intravenous administration of dantrolene 2.4 mg/kg results in plasma concentration of 4.2 μg/ml (Krause et al., 2004), which is 12.5 μM. In animal studies, dantrolene was used in rat or mice at the dosage of 5, 10, or even 25–50 mg/kg (Berg et al., 1995; Wei and Perry, 1996; Niebauer and Gruenthal, 1999; Schneider et al., 2001; Popescu et al., 2002; Ackel et al., 2005). Both 25 and 50 mg/kg caused the death of animals. Considering the long-term trial, we selected a “low end” dose of 5 mg/kg with twice per week drug delivery. Dantrolene is a potent muscle relaxant and has sedative effects, and we indeed noticed that the mice were much less active for several hours after dantrolene feeding. However, none of the mice died during the 14 months trial and all mice could recover within several hours after dantrolene feeding and start to behave normally.

In agreement with the previous studies (Wei and Perry, 1996), we found that dantrolene crossed the brain–blood barrier poorly, reaching concentration of only 67 nM in the mouse brains (30 min after feeding). We reasoned that dantrolene is a highly lipophilic substance that may accumulate in the membranes,
which makes its membrane concentration high enough to block RyanR and store-operated calcium (SOC) and to provide protective effects. Consistent with this interpretation, neuroprotective effects of peripherally administered dantrolene were observed in whole-animal models of cerebral ischemia (Wei and Perry, 1996) and in studies of kainic acid-induced excitotoxicity paradigm (Berg et al., 1995; Niebauer and Gruenthal, 1999; Schneider et al., 2001; Popescu et al., 2002). Thus, it appears that concentrations of dantrolene reached in the brain in these studies were sufficient to block neuronal RyanR and SOC and to cause neuroprotective effects. Similarly, in our experiments we discovered that feeding SCA3-YAC-84Q mice with 5 mg/kg dantrolene significantly improved their performance in motor coordination assay (Figs. 7, 8). More importantly, there was significantly less neuronal loss in pontine nuclei and substantia nigra regions of the mice fed with dantrolene (Fig. 9, Table 1). This indicates that dantrolene is neuroprotective and supports the hypothesis that deranged calcium signaling may play a significant role in the pathogenesis of SCA3.

In our study, we established the connection between deranged intracellular Ca^{2+} signaling and neurodegeneration in SCA3. Together with our previous studies of HD (Tang et al., 2003, 2005, 2007; Bezprozvanny and Hayden, 2004; Wu et al., 2006), these results suggest that abnormal neuronal Ca^{2+} signaling may play a role in pathogenesis of many polyglutamine expansion disorders. Short-term delivery of dantrolene has been previously demonstrated to be neuroprotective in acute excitotoxic paradigms, such as cerebral ischemia (Wei and Perry, 1996) and kainic acid injection model (Berg et al., 1995; Niebauer and Gruenthal, 1999; Schneider et al., 2001; Popescu et al., 2002). Here, for the first time, we demonstrated protective effects of long-term treatment with dantrolene in an animal model of a chronic neurodegenerative disorder. Also, for the first time, we demonstrated that a clinically relevant drug exerts beneficial effects in an animal model of SCA3. Our results indicate that calcium-signaling stabilizers such as dantrolene should be considered as potential therapeutics for the treatment of SCA3 patients and possibly other neurodegenerative disorders.

References


